Thromboembolism in patients with melanoma receiving immune checkpoint inhibitors: incidence and risk factors.

ABSTRACT:

Background

Immune checkpoint inhibitors (ICIs) may increase the incidence of thromboembolisms (TEs). In patients with melanoma, the risk of TE and its association with the disease setting remains largely unknown. This study investigated the incidences of arterial thromboembolism (ATE) and venous thromboembolism (VTE) and associated risk factors in ICI-treated patients with melanoma in the advanced and adjuvant disease settings.

Patients and methods

ATE and VTE incidences were retrospectively collected from patients receiving ICI in the advanced (irresectable stage III/IV) or adjuvant (stage III/IV, after complete resection) disease setting until 2 years or after censoring. Associations between characteristics and ATE/VTE were analyzed using the Fine-Gray model, with all-caus

SUBMITTER: van Dorst DCH 

PROVIDER: S-EPMC12275875 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature